Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress

Summary

This is a Phase 2 randomized controlled study to assess the safety and efficacy of COVI-MSC in the setting of current standard of care treatments for COVID-19 infection in hospitalized subjects with acute respiratory distress syndrome.

Timeline

Start

2021-11-16

Primary completion

2022-08-29

Completion

2022-11-23

Outcome

Outcome not reported

Stopped (Enrollment): “Due to considerably slow enrollment, unable to reach enrollment targets”

Drugs

Indications